EMERYVILLE, Calif., July 27, 2016 – Mercator MedSystems, Inc., has announced the enrollment of the first critical limb ischemia (CLI) patients in the LIMBO-ATX trial, the design of which was approved by the U.S. Food and Drug Administration (FDA) under an Investigation New Drug (IND) application. The study is designed to measure the benefit of localized drug delivery using the company’s proprietary Bullfrog® Micro-Infusion Device in combination with opening obstructed arteries in the lower leg. Patients were enrolled by Dr. George Adams at the University of North Carolina REX Hospital in Raleigh, NC and by Dr. Jason Yoho of the New Braunfels Cardiology Group at Guadalupe Regional Hospital in Seguin, TX, and both enrollments were in conjunction with an atherectomy procedure.